Breaking News

Fujirebio Unveils CSF Assay to Assist Alzheimer’s Research

Measuring human cerebrospinal fluid can help mark neuropathological changes associated with Alzheimer’s disease.

Author Image

By: Patrick Lavery

Content Marketing Editor

Fujirebio is launching a human cerebrospinal fluid (CSF) assay as part of its continuing efforts to detect Alzheimer’s disease-related pathology. However, the Lumipulse G pTau217 (Tau phosphorylated at threonine 217) CSF chemiluminescent enzyme immunoassay (CLEIA) assay applies to research use only. It is optimized for Fujirebio’s fully automated immunoassay analyzers. Fujirebio Takes Next Step in Alzheimer’s Work In a press release, Fujirebio characterized Alzheimer’s disease as having...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters